STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #623 by analyst upside · 2026-06-27
VKTX
Viking Therapeutics, Inc.
Healthcare · Market Cap $4B · P/E 0x
ANALYST PRICE TARGET
+143.4%
implied upside to consensus target
Current Price $38.04
Consensus Target $92.58
Bull Target $125.0
Bear Target $34.0
Analysts Covering 19
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
12
Hold
2
Sell
0
52-Week Low $22.96
52-Week High $43.15
YTD Return +7.4%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) N/A
Forward P/E -8.3x
EPS (TTM) $-4.15
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $22.96
52-Week High $43.15
Current Price $38.04
Bear Target $34.0
Bull Target $125.0
● Now $38.04 ● Target $92.58
TRADING DATA
Avg Volume 2.3M
YTD Return +7.4%
Analyst Count 19
Consensus Buy
Upside to Target +143.4%
Last Updated 2026-06-27

ANALYST SUMMARY

Viking Therapeutics, Inc. (VKTX) is currently trading at $38.04 with a Wall Street consensus price target of $92.58, implying potential upside of 143.4% over the next 12 months. 19 analysts currently cover VKTX, with a consensus rating of Buy - 89% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $125.0, while the most cautious has a target of $34.0.

VKTX operates in the Healthcare sector with a market capitalisation of $4B. The stock is up 7.4% year-to-date and is currently trading near the upper end of its 52-week range of $22.96 – $43.15.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for VKTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Lake Street ● Initiated
Buy 2026-05-28 27% win rate (11 calls)
BTIG reit
Buy → Buy 2026-05-01 38% win rate (8 calls)
Cantor Fitzgerald — Reiterated
Overweight → Overweight 2026-04-30 40% win rate (10 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-03-23 31% win rate (48 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2025-11-12 Building track record
Canaccord Genuity ● Initiated
Buy 2025-10-29 Building track record
JP Morgan — Reiterated
Overweight → Overweight 2025-10-24 43% win rate (7 calls)
Morgan Stanley — Reiterated
Overweight → Overweight 2025-10-23 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
23/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →